Top Ten Heavy News of the Biomedical Industry in 2014

In a blink of an eye, there is only one last month left in 2014. For the biomedical industry, one of the fastest growing industries in the world in recent years, there have been surprises, losses, breakthroughs and regrets in this year. Xiaobian first led everyone to review the most attractive 10 pieces of the biomedical industry in 2014.

1. Anjin Company lays off 2,900 people and reorganizes R&D units.

An important theme of the biomedical industry in recent years has been the restructuring of R&D units of biopharmaceutical companies. With the globalization of pharmaceutical companies and the arrival of patent cliffs, many companies are realizing the need to reform their R&D departments. Among them, Amgen has laid off a large number of layoffs on the company's R&D department in Seattle, with a list of more than 2,900 people, which has caused widespread concern in the market. This change has naturally attracted the attention and support of many analysts.

Not only Amgen, but many other biopharmaceutical giants such as GlaxoSmithKline have also carried out similar reforms in order to make the company's R&D system more competitive. And this news of Amgen can also be seen as a microcosm of the changes in the biomedical industry.

Second, the Caitlin Cancer Research Center CAR-T therapy two patients died

If there is any bright spot in the research and development of biomedical industry in 2014, chimeric antigen receptor-T cell therapy is definitely a well-deserved hotspot. Many biopharmaceutical giants and industry analysts see this therapy as a hope for a new generation of cancer therapies.

However, two patients in the CAR-T project conducted by the Caitlin Cancer Research Center this year died of cytokine release syndrome, which led to the emergency stop of the project. This result has also caused vigilance from agencies such as the FDA. Pioneers in the development of CAR-T therapy, including Novartis and Juno, also recognized the threat of cytokine storms and further improved the experimental design. It can be said that this incident has prompted all CAR-T R&D competitors to think more fully about the problems and challenges they face.

Third, the anti-PD-1 drug nivolumab developed by Ono has been approved by the Japanese market, and has won the top spot in the world of biomedicine.

In 2014, both the pharmaceutical management department and the biopharmaceutical company paid more attention to cancer immunotherapy research. Ono is the leader in PD-1 drug discovery. The anti-PD-1 oncology drug nivolumab developed by the company was approved by the relevant Japanese medical management department and successfully landed in the Japanese market.

Although the Japanese market is not very strategic for many biopharmaceutical companies, nivolumab has won worldwide attention as the world's first anti-PD-1 drug. And the giant behind it, Squibb, will undoubtedly take the lead in the competition for PD-1 drug development.

Aquatic Extract

We are a professional Chinese manufacturer of Aquatic Extract;we supply various products of Aquatic Extract, and can providing product images and basic parameters with each Fish Collagen, Oyster Extract, Turtle Extract, Sea Cucumber Extract and Krill Oil. We have the perfect after-sales service and technical support. Please do not hesitate to contact us, Look forward to your cooperation!

Fish Collagen,Oyster Extract,Turtle Extract,Sea Cucumber Extract,Krill Oil

Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobio.com